These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19674776)

  • 1. Homoeopathy: not a matter for drug-regulatory authorities.
    Garattini S; Bertelé V
    Lancet; 2009 Nov; 374(9701):1578-80. PubMed ID: 19674776
    [No Abstract]   [Full Text] [Related]  

  • 2. The First Amendment and FDA restrictions on off-label uses: the call for a new approach.
    Leghorn J; Brophy E; Rother P
    Food Drug Law J; 2008; 63(2):391-406. PubMed ID: 18561466
    [No Abstract]   [Full Text] [Related]  

  • 3. Legislative and regulatory modernization for therapeutic products.
    Maher M
    J Popul Ther Clin Pharmacol; 2010; 17(3):e341-8. PubMed ID: 21041867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drug prescriptions outside the marketing product license and its responsibilities].
    Gromb S; Maurain C; Carbonnel S
    Presse Med; 2000 May 27-Jun 3; 29(19):1053-7. PubMed ID: 10874916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homoeopathic product licence. MHRA label seems to be illegal.
    Colquhoun D
    BMJ; 2009 Jun; 338():b2333. PubMed ID: 19509427
    [No Abstract]   [Full Text] [Related]  

  • 6. Raising the bar for market authorisation of new drugs.
    Naci H; Cylus J; Vandoros S; Sato A; Perampaladas K
    BMJ; 2012 Aug; 345():e4261. PubMed ID: 22872693
    [No Abstract]   [Full Text] [Related]  

  • 7. The future of off-label marketing regulations in the post-Sorrell era.
    Iraggi J
    Seton Hall Law Rev; 2013; 43(3):1137-63. PubMed ID: 23802338
    [No Abstract]   [Full Text] [Related]  

  • 8. Assessing supplement safety--the FDA's controversial proposal.
    Cohen PA
    N Engl J Med; 2012 Feb; 366(5):389-91. PubMed ID: 22276780
    [No Abstract]   [Full Text] [Related]  

  • 9. Off-label uses of drugs and medical devices: should the FDA crack down?
    Margolis RE
    Healthspan; 1993 Jan; 10(1):18-9. PubMed ID: 10124289
    [No Abstract]   [Full Text] [Related]  

  • 10. Marketing health care products on the Internet: a proposal for updated federal regulations.
    Green K
    Am J Law Med; 1998; 24(2-3):365-86. PubMed ID: 9702278
    [No Abstract]   [Full Text] [Related]  

  • 11. Is it a cosmetic, a drug, or both? (Or is it soap?).
    Center for Safety and Applied Nutrition/Office of Cosmetics and Colors US Food and Drug Administration
    Plast Surg Nurs; 2008; 28(4):195-7. PubMed ID: 19092587
    [No Abstract]   [Full Text] [Related]  

  • 12. Regulators need to regulate. For health and safety issues, the nation needs watchdogs to be on guard.
    May D
    Mod Healthc; 2010 Mar; 40(9):16. PubMed ID: 20344831
    [No Abstract]   [Full Text] [Related]  

  • 13. [Medicinal products--legislation, regulations].
    Wander M
    Pflege Aktuell; 1998 Oct; 52(10):564-8. PubMed ID: 9842354
    [No Abstract]   [Full Text] [Related]  

  • 14. Future of the European Union regulatory network in the context of the uptake of new medicines.
    Hoebert JM; Irs A; Mantel-Teeuwisse AK; Leufkens HG
    Br J Clin Pharmacol; 2013 Jul; 76(1):1-6. PubMed ID: 23043328
    [No Abstract]   [Full Text] [Related]  

  • 15. Using a drug-safety tool to prevent competition.
    Sarpatwari A; Avorn J; Kesselheim AS
    N Engl J Med; 2014 Apr; 370(16):1476-8. PubMed ID: 24738666
    [No Abstract]   [Full Text] [Related]  

  • 16. Should Anthroposophic Medicinal Products Be Regulated in Europe?
    Michaux G
    Eur J Health Law; 2017 Mar; 24(1):46-66. PubMed ID: 29210253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Canadian perspective: trends in drug and medical device class actions in Canada.
    Vernon W
    Food Drug Law J; 2006; 61(3):569-76. PubMed ID: 16989040
    [No Abstract]   [Full Text] [Related]  

  • 18. Adjusting Europe's drug regulation to public health needs.
    Garattini S; Bertele V
    Lancet; 2001 Jul; 358(9275):64-7. PubMed ID: 11454401
    [No Abstract]   [Full Text] [Related]  

  • 19. [Increased commercial financing of national Medical Product Agencies within the EU].
    Ramel B
    Lakartidningen; 2003 Jan; 100(5):338-9. PubMed ID: 12607381
    [No Abstract]   [Full Text] [Related]  

  • 20. Health protection in Europe after 1992.
    de Bijl N
    Med Law; 1993; 12(1-2):71-6. PubMed ID: 8377623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.